EV-Pem
Cross-source consensus on EV-Pem from 1 sources and 4 claims.
1 sources · 4 claims
Uses
Benefits
Risks & contraindications
Evidence quality
Highlighted claims
- EV-Pem is not cost-effective at the standard UK willingness-to-pay threshold of £30,000 per QALY. — Cost-effectiveness analysis of enfortumab vedotin and pembrolizumab versus chemotherapy for patients with untreated advanced urothelial cancer in the United Kingdom
- EV-Pem improved progression-free and overall survival compared with chemotherapy in EV-302. — Cost-effectiveness analysis of enfortumab vedotin and pembrolizumab versus chemotherapy for patients with untreated advanced urothelial cancer in the United Kingdom
- EV-Pem is a first-line treatment combination for locally advanced or metastatic urothelial carcinoma based on the EV-302 trial. — Cost-effectiveness analysis of enfortumab vedotin and pembrolizumab versus chemotherapy for patients with untreated advanced urothelial cancer in the United Kingdom
- EV-Pem requires substantial price reductions to meet NICE cost-effectiveness standards. — Cost-effectiveness analysis of enfortumab vedotin and pembrolizumab versus chemotherapy for patients with untreated advanced urothelial cancer in the United Kingdom